ArticleMikrochimica acta2026
Label-free paper-based electrochemical aptasensor with tunable selectivity for assessing neurotransmitter imbalance in Alzheimer's disease.
Article in Mikrochimica acta, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A paper-based electrochemical aptasensor (PEA) is reported for the simultaneous detection of extracellular dopamine (DA) and serotonin (SE) in human brain samples, enabling the assessment of neurotransmitter imbalances associated with Alzheimer's disease (AD). The PEA integrates a dual-selectivity strategy that combines aptamer-mediated molecular recognition with potential-resolved electrochemical neurotransmitters discrimination, allowing reliable differentiation between healthy and AD-diagnosed left prefrontal cortex tissues based on altered dopaminergic and serotonergic levels. Thiolated aptamers immobilized onto gold nanoparticles (AuNPs) at the paper electrode interface provide selective neurotransmitter biorecognition, while the distinct oxidation potentials of DA (+ 0.10 V) and SE (+ 0.25 V vs. Ag/AgCl) enable their label-free, simultaneous quantification on a single disposable electrode. The PEA read biologically meaningful concentration shifts across a clinically relevant dynamic range, spanning levels characteristic of healthy tissue to those observed in advanced pathological stages. The PEA approach highlights its potential for liquid biopsy-oriented neurochemical monitoring and supports its application in multiplexed biosensing within organ-on-a-chip systems, enabling early diagnostic strategies for neurodegenerative diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.